Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Diluted Average) (2021 - 2025)

Sunshine Biopharma filings provide 5 years of Shares Outstanding (Diluted Average) readings, the most recent being $2.7 million for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 321.53% to $2.7 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.7 million, a 321.53% increase, with the full-year FY2024 number at $701749.0, up 5371.73% from a year prior.
  • Shares Outstanding (Diluted Average) hit $2.7 million in Q1 2025 for Sunshine Biopharma, up from $701749.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $25.7 million in Q3 2023 to a low of $12825.0 in Q4 2023.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $4.0 million (2022), compared with a mean of $8.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 99.92% in 2023 and later surged 5371.73% in 2024.
  • Sunshine Biopharma's Shares Outstanding (Diluted Average) stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then plummeted by 99.92% to $12825.0 in 2023, then surged by 5371.73% to $701749.0 in 2024, then soared by 285.22% to $2.7 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $2.7 million (Q1 2025), $701749.0 (Q4 2024), and $641310.0 (Q1 2024) per Business Quant data.